Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.60 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.60 |
| ▸ | OSBP | P22059 | 1/20 | 0.60 |
| ▸ | RORC | P51449 | 1/20 | 0.60 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.60 |
| ▸ | POLA1 | P09884 | 1/20 | 0.57 |
| ▸ | GRIN1 | Q05586 | 12/20 | 0.56 |
| ▸ | GRIN2B | Q13224 | 12/20 | 0.56 |
| ▸ | GRIN2A | Q12879 | 10/20 | 0.55 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL998341 | 1.00 | USP2 (0.60) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL19691912 | 0.92 | USP2 (0.60) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL3359948 | 0.92 | USP2 (0.60) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL1050027 | 0.91 | USP2 (0.59) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL22658123 | 0.91 | USP2 (0.59) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL8205164 | 0.91 | USP2 (0.59) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL1081197 | 0.91 | USP2 (0.59) | USP2CYP46A1LMNAABCB1OSBP | |
| Hydrochloric Acid SCHEMBL11907786 | 0.91 | USP2 (0.58) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL18797660 | 0.91 | USP2 (0.58) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL2440566 | 0.91 | OSBP (0.58) | USP2CYP46A1LMNAABCB1OSBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3357491-B1 | PHARMACEUTICAL COMPOSITION FOR DELIVERING AN ANIONIC DRUG | SAMYANG BIOPHARMACEUTICALS (KR) | 2021-06-02 | — | — | EP | claimed |
| EP-2833869-B1 | METHOD OF PREPARING COMPOSITION FOR DELIVERING AN ANIONIC DRUG | SAMYANG BIOPHARMACEUTICALS (KR) | 2020-10-28 | — | — | EP | claimed |
| US-20190336611-A1 | HYBRID CARRIERS FOR NUCLEIC ACID CARGO | CUREVAC AG (DE) | 2019-11-07 | — | — | US | claimed |
| EP-3468608-A1 | HYBRID CARRIERS FOR NUCLEIC ACID CARGO | CureVac AG (DE) | 2019-04-17 | — | — | EP | claimed |
| EP-3468612-A1 | HYBRID CARRIERS FOR NUCLEIC ACID CARGO | CureVac AG (DE) | 2019-04-17 | — | — | EP | claimed |
| EP-2217221-B1 | LDL-LIKE CATIONIC NANOPARTICLES FOR DELIVERYING NUCLEIC ACID GENE, METHOD FOR PREPARING THEREOF AND METHOD FOR DELIVERYING NUCLEIC ACID GENE USING THE SAME | KOREA ADVANCED INST SCI & TECH (KR) | 2018-06-27 | — | — | EP | claimed |
| WO-2017212008-A1 | HYBRID CARRIERS FOR NUCLEIC ACID CARGO | CUREVAC AG (DE) | 2017-12-14 | — | — | WO | claimed |
| WO-2017212006-A1 | HYBRID CARRIERS FOR NUCLEIC ACID CARGO | CUREVAC AG (DE) | 2017-12-14 | — | — | WO | claimed |
| CN-117462515-A | Kit for rapidly preparing lipid nucleic acid nano-drug and preparation method thereof | 上海镁纳生物科技有限公司 | 2024-01-30 | — | — | CN | disclosed |
| CN-117377467-A | Kit for preparing drug-containing and amphiphilic polymer-free nanoparticles | 三养控股公司 | 2024-01-09 | — | — | CN | disclosed |
| CN-117241791-A | Composition for drug delivery comprising nanoparticles free of amphiphilic polymer | 三养控股公司 | 2023-12-15 | — | — | CN | disclosed |
| WO-2023147552-A1 | RADIOSENSITIZING COMPOSITIONS AND METHODS OF USE THEREOF | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2021125805-A1 | KIT FOR PREPARING NANOPARTICLE COMPOSITION FOR DRUG DELIVERY, COMPRISING POLYLACTIC ACID SALT | 주식회사 삼양홀딩스 | 2021-06-24 | — | — | WO | disclosed |
| EP-3695850-A1 | CARRIER FOR NEGATIVELY CHARGED DRUGS COMPRISING A CATIONIC LIPID AND A PREPARATION METHOD THEREOF | Samyang Biopharmaceuticals Corporation (KR) | 2020-08-19 | — | — | EP | disclosed |
| WO-2019098691-A9 | COMPOSITION AND METHOD FOR FREEZE-DRYING PHARMACEUTICAL COMPOSITION CONTAINING ANIONIC DRUG | 주식회사 삼양바이오팜 | 2019-08-29 | — | — | WO | disclosed |
| EP-3468608-A1 | HYBRID CARRIERS FOR NUCLEIC ACID CARGO | CureVac AG (DE) | 2019-04-17 | — | — | EP | disclosed |
| EP-3468612-A1 | HYBRID CARRIERS FOR NUCLEIC ACID CARGO | CureVac AG (DE) | 2019-04-17 | — | — | EP | disclosed |
| EP-3391875-A1 | METHOD FOR PREPARING POLYMERIC MICELLE CONTAINING ANIONIC DRUG | Samyang Biopharmaceuticals Corporation (KR) | 2018-10-24 | — | — | EP | disclosed |
| WO-2017212006-A1 | HYBRID CARRIERS FOR NUCLEIC ACID CARGO | CUREVAC AG (DE) | 2017-12-14 | — | — | WO | disclosed |
| WO-2017212008-A1 | HYBRID CARRIERS FOR NUCLEIC ACID CARGO | CUREVAC AG (DE) | 2017-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190336611-A1 | HYBRID CARRIERS FOR NUCLEIC ACID CARGO | PHAX, LNPEP, PITPNB | USP2 3765/4885CYP46A1 766/4885LMNA 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.